Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARSARC: Berzosertib + Gemcitabine in Advanced Leiomyosarcoma
NCT04807816Phase 2Completed
- Sponsor
- Institut Bergonié
- Start
- Feb 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of berzosertib in leiomyosarcoma (LMS), sponsored by Institut Bergonié. Started Feb 2022; status: completed.
02
Drugs
berzosertib
03
Conditions
leiomyosarcoma (LMS)
Beyond the preview
Go deeper on NCT04807816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04807816.